| Heading: |
Bacteriophages |
| Question ID: |
1792312 |
| UIN: |
44138 |
| House: |
Commons |
| Date tabled: |
2025-04-03 |
| Asking Member ID: |
5111 |
| Asking Member display name: |
Martin Wrigley
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Martin Wrigley
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make a comparative assessment of the effectiveness of phage therapy regulatory frameworks in (a) Belgium, (b) Canada, (c) France, (d) the US and (e) Australia; whether he plans to adopt |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-09 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The United Kingdom’s regulatory framework supports patient access to phage therapy and is in line with many other national regulatory authorities. We continue to keep the regulatory framework for phage therapies under review, aligning where necessary with... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |